Trex Wind-down, Inc. (TMBRQ)
- Previous Close
0.0002 - Open
0.0002 - Bid --
- Ask --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0001 - 0.9609 - Volume
10 - Avg. Volume
3,815 - Market Cap (intraday)
686 - Beta (5Y Monthly) -1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 6, 2024.
www.timberpharma.comRecent News: TMBRQ
Performance Overview: TMBRQ
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMBRQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMBRQ
Valuation Measures
Market Cap
343.00
Enterprise Value
-1.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-137.27%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.93M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.52M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.18M
Research Analysis: TMBRQ
Company Insights: TMBRQ
TMBRQ does not have Company Insights